Cargando…

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma

Melanoma is the deadliest form of skin cancer and has an incidence that is rising faster than any other solid tumor. Metastatic melanoma treatment has considerably progressed in the past five years with the introduction of targeted therapy (BRAF and MEK inhibitors) and immune checkpoint blockade (an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Teresa, Amaria, Rodabe N., Spencer, Christine, Reuben, Alexandre, Cooper, Zachary A., Wargo, Jennifer A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chinese Anti-Cancer Association 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296084/ https://www.ncbi.nlm.nih.gov/pubmed/25610709 http://dx.doi.org/10.7497/j.issn.2095-3941.2014.04.002

Ejemplares similares

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

Update on use of aldesleukin for treatment of high-risk metastatic melanoma
por: Amaria, Rodabe N, et al.
Publicado: (2015)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM)
por: Kim, Dae Won, et al.
Publicado: (2015)

Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients
por: Tetzlaff, Michael T., et al.
Publicado: (2018)

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
por: Cooper, Zachary A., et al.
Publicado: (2016)

Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials
por: Pelster, Meredith S., et al.
Publicado: (2019)

Molecular and immune heterogeneity in synchronous melanoma metastases
por: Reuben, Alexandre, et al.
Publicado: (2015)

Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment
por: Duke, Taylor C., et al.
Publicado: (2020)

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2018)

Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
por: L’Orphelin, Jean-Matthieu, et al.
Publicado: (2023)

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study
por: Qin, Yong, et al.
Publicado: (2017)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
por: Changizzadeh, Pouyan N., et al.
Publicado: (2017)

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
por: Murakami, Naoka, et al.
Publicado: (2016)

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
por: Murakami, Naoka, et al.
Publicado: (2016)

Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report
por: Langan, Ewan A., et al.
Publicado: (2021)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Immune checkpoint inhibitor‐related gastritis in a patient with metastatic melanoma
por: Sugiyama, Yuya, et al.
Publicado: (2021)

The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma
por: Ogata, Dai, et al.
Publicado: (2021)

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
por: Sloane, Robert A. Szczepaniak, et al.
Publicado: (2021)

Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma
por: Pennington, Thomas E, et al.
Publicado: (2022)

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
por: Petrelli, Fausto, et al.
Publicado: (2016)

Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review
por: Li, Jiarui, et al.
Publicado: (2020)

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2022)

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
por: Mesti, Tanja, et al.
Publicado: (2023)

Machine Learning Improves the Prediction of Responses to Immune Checkpoint Inhibitors in Metastatic Melanoma
por: Tabari, Azadeh, et al.
Publicado: (2023)

Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
por: Haist, Maximilian, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
por: Wölffer, Marcus, et al.
Publicado: (2022)

Diffuse Metastatic Melanoma in the GI Lumen Following Immune Checkpoint Inhibitor Colitis Treatment
por: Sperling, Gabriel, et al.
Publicado: (2022)

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
por: Khair, Duaa O., et al.
Publicado: (2019)

Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma
por: Tomsitz, Dirk, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Melanoma and HIV Infection
por: Marra, Antonio, et al.
Publicado: (2017)

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
por: Heppt, Markus V., et al.
Publicado: (2019)

The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors
por: Wheeler, Caroline E., et al.
Publicado: (2023)

Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
por: Guida, M., et al.
Publicado: (2021)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e0g5pd259um11kbsjde4fdljm4